Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

12 November 2025

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Enclosed herewith are the copies of the press releases titled "Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek® 2025" and "Sun Pharma Presents Data from Phase 1b/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions," which shall be released after this intimation.

For **Sun Pharmaceutical Industries Limited**

Anoop Anjanikumar Deshpande
Digitally signed by Anoop Anjanikumar Deshpande
Date: 2025.11.12 15:56:37 +05'30'

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek® 2025

Thirteen weeks of utreglutide dosing in individuals with obesity and MASLD showed significant body weight reduction of 6.8% and change in waist circumference of 6.8% at week 14

In individuals with overweight and obesity, once weekly utreglutide dosing for ten weeks demonstrated body weight loss of 6.8% and TC and LDL reductions of ~10% with pronounced effect on LDL in individuals with higher baseline value

Utreglutide was well tolerated, with the most frequent adverse events being gastrointestinal, consistent with the class of drugs

MUMBAI, India and PRINCETON, N.J., November 12, 2025 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) announced two poster presentations at the ObesityWeek® 2025 Scientific Sessions held from November 4-7, 2025, in Atlanta, USA.

In one of the posters, data from a subgroup of Phase 1b/2a Study of utreglutide (GL0034) in overweight and obese individuals and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in a phase 1b/2a study was presented. The subgroup comprised individuals with Class III Obesity and MASLD. Thirteen weeks of utreglutide dosing in individuals with obesity and MASLD showed body weight and waist circumference reduction, improved cardio-metabolic markers, significant liver fat loss in 31% of subjects, and reduced urate levels, indicating potential benefits for MASLD resolution and co-morbid conditions like atherosclerosis and renal disease. The drug was well tolerated, with the most common adverse events occurring in ≥5 participants receiving GL0034 were nausea, diarrhoea and vomiting. The study was conducted in Australia.

In the other poster, data from a 10-week safety and efficacy study administering utreglutide (GL0034) in individuals with obesity was presented. Once-weekly utreglutide dosing over ten weeks in individuals with overweight and obesity led to 6.8% body weight loss, about 10% TC and LDL reduction, 16.3% ApoB drop, and significant improvements in inflammatory markers, liver enzymes, and fatty liver index. The study suggested that the drug may show promise for managing cardiovascular risks, with or without type 2 diabetes. The study was conducted in Belgium.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

"Obesity and related metabolic conditions continue to challenge the health and well-being of individuals worldwide," said Dilip Shanghvi, Chairman, Sun Pharma. "At Sun Pharma, we are committed to exploring innovative solutions that can help improve patient outcomes. The early findings with utreglutide are promising and reinforce our focus on developing therapies that address unmet needs in a meaningful and accessible way."

"We observed encouraging reductions in liver fat and improvements across key metabolic parameters with utreglutide in individuals with obesity and MASLD. In a separate study, the treatment also showed favorable effects on lipid profiles and inflammatory markers in individuals with obesity without diabetes. Utreglutide was well tolerated, and these early findings support continued investigation across broader patient populations.", said said Rohit Loomba, Professor of Medicine (with tenure), Chief, Division of Gastroenterology and Hepatology, University of California at San Diego.

GL0034 was discovered and is being developed by Sun Pharma. Further clinical studies are planned to assess clinical safety and efficacy.

Utreglutide (GL0034) in Subgroup of Individuals with Class III Obesity and MASLD: Phase 1b/2a Study

A Phase 1b/2a Study of The Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in the Treatment of MASLD. [Poster, Tuesday, November 4, 2025, 7:30pm – 8:30pm ET, Exhibit Hall A1, Presented by Dr. Rajamannar Thennati]

- Participants (n=48; BMI ≥30 kg/m^2; Controlled attenuated parameter (CAP) ≥306 dB/m via FibroScan®; Liver fat content ≥10%, as assessed by MRI-PDFF) were randomized 3:1 to treatment with GL0034 (uptitration from 0.4 mg-1.6mg for 10 weeks and fixed dose of 2.4 mg for 3 weeks; total dose 17.6 mg) or placebo for 13 weeks. Data from strata of participants with Class III obesity (23-69 years of age) is presented (13 in GL0034 treatment group and 5 placebo). At Week 14, the GL0034-treated participants achieved mean percent change of -6.8% in body weight, which sustained beyond initial treatment exposure through Week 17. It was accompanied by mean change of 3.7 inches in waist circumference at Week 14 in GL0034-treated participants against -0.5 inches for placebo-treated participants.
- Triglyceride and total cholesterol levels were significantly decreased (P<0.05) along with ApoB (P<0.01) from baseline in participants treated with GL0034. The relative liver fat content in GL0034-treated participants reduced significantly from baseline (MRI-PDFF, P<0.001) as compared to placebo 1.3% (MRI-PDFF) and 31% achieved more than 30% liver fat reduction. The mean percent change from baseline in urate levels were -11.5% for GL0034-treated participants as compared to 0.6% in placebo-treated participants, and the number of subjects with urate level of less than 0.35 mmol/L doubled at week 14 as compared to baseline in GL0034-treated group.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

- The most common AEs occurring in participants receiving GL0034 were gastrointestinal with mild-moderate intensity. They included nausea, while diarrhoea and vomiting were reported by only 15% of participants.

Utreglutide (GL0034) in Individuals with Obesity: 10-week Safety and Efficacy Study Outcomes

A Proof of Concept Study of The Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Overweight Obese Individuals Without Diabetes. [Poster, Tuesday, November 4, 2025, 7:30pm – 8:30pm ET, Exhibit Hall A1, Presented by Dr. Rajamannar Thennati]

- Participants (n=20; BMI ≥28 and ≤45 kg/m^2) were randomized 4:1 to once-weekly treatment with GL0034 (uptitration from 0.4 mg–2 mg) or placebo for 10 weeks. At week 11, GL0034 treated participants achieved placebo corrected mean percent change in body weight of -6.5 (P<0.001) at total dose of 14.2 mg, which sustained beyond initial treatment exposure through week 14 at -6.2% (P<0.001).
- Total cholesterol levels were significantly decreased from baseline in GL0034-treated participants with mean percent changes of -11.9 (P<0.01) along with LDL (-9.6%; P<0.05) at Week 10, compared to an increase of 8.4% and 23.2% in placebo-treated individuals. In 57% of GL0034-treated participants (baseline LDL more than 120 mg/dl) the mean BL of 153 mg/dL reduced by 31 mg/dL. Atherogenic ApoB levels reduced with significance (P<0.001); hsCRP levels reduced by 31% and 29% participants achieved less than 1.5 mg/L hsCRP levels. The mean change in ALT levels was -13 U/L in GL0034-treated participants.
- Most common AEs occurring in GL0034-treated participants were gastrointestinal, with mild to moderate intensity and observed in <20% participants.

About GL0034

GL0034 (utreglutide) is an investigational novel glucagon-like peptide 1 receptor agonist (GLP-1RA) in development as a once-weekly, long-acting, antidiabetic medication in patients with obesity and type 2 diabetes. Further clinical studies are planned to assess clinical safety and effectiveness.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).

Disclaimer

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contacts

Investors

Dr. Abhishek Sharma
Tel + 91 22 4324 4324, Ext 2929
Tel Direct + 91 22 43242929
Mobile + 91 98196 86016
E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh
Tel + 91 22 4324 4324, Ext 5373
Tel Direct + 91 22 43245373
Mobile + 91 98104 71414
E mail gaurav.chugh@sunpharma.com

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma Presents Data from Phase 1b/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions

Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist showed Weight loss of 8% at week 14, Reduced Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity

MUMBAI, India and PRINCETON, N.J., November 12, 2025 – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) recently announced results from its Phase 1a/2b Study evaluating the tolerability, safety, pharmacokinetics and pharmacodynamics of GL0034, a novel long-acting GLP-1 receptor agonist, in post-menopausal females with obesity. The data were highlighted in poster presentation at the American Heart Association's (AHA) Scientific Sessions held from November 7-10, 2025, in New Orleans, USA.

The Phase 1b/2a study in Australia evaluated weekly subcutaneous utreglutide in post-menopausal women with obesity and MAFLD (Metabolic Dysfunction-associated Fatty Liver Disease). Participants experienced meaningful weight loss and waist circumference reduction, with a notable proportion achieving clinically significant outcomes compared to placebo.

Additional metabolic improvements included improved systolic blood pressure, reduced liver fat, and favorable changes in biomarkers linked to fibrosis and insulin sensitivity. The treatment also lowered serum uric acid levels, reinforcing its potential in addressing multiple aspects of metabolic dysfunction in this high-risk population.

Once weekly utreglutide dosing for 13 weeks was well tolerated in post-menopausal female participants with obesity and MAFLD. The most frequent AEs were gastrointestinal in nature-nausea, diarrhoea, and vomiting - which is consistent with the incretin class. One participant had a serious Treatment-Emergent Adverse Event, which was unrelated to the treatment.

"Obesity and metabolic liver diseases continue to place a growing burden on public health, especially among post-menopausal women who face unique challenges. The results from our early-stage study with utreglutide are encouraging and reflect our commitment to advancing therapies that can make a meaningful difference in patients' lives. We're pleased with the progress and remain focused on supporting better health outcomes." said Dilip Shanghvi, Chairman, Sun Pharma.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

"We observed encouraging reductions in liver fat and improvements across key metabolic parameters with utreglutide in post-menopausal women with obesity and MASLD." said Rohit Loomba, Professor of Medicine (with tenure), Chief, Division of Gastroenterology and Hepatology, University of California at San Diego. The treatment was well tolerated, with low discontinuation rate. These findings highlight utreglutide's potential in addressing MAFLD and related metabolic conditions. We look forward to seeing how this molecule progresses through future clinical development."

GL0034 was discovered and is being developed by Sun Pharma. Further clinical studies are planned to assess clinical safety and efficacy.

GL0034 Poster Presentation at the AHA 2025 Scientific Sessions

A Phase 1b/2a Study of The Novel GLP-1 Receptor Agonist GL0034 (utreglutide) in the Treatment of MASLD. [Moderated Digital PosterMP444, Saturday, November 8, 2025, 01:11pm – 01:16pm CT, Population Science Zone, Moderated Digital Poster 11, Presented by Dr. Rajamannar Thennati]

- Participants (n=48; BMI ≥30 kg/m^2 Controlled attenuated parameter (CAP) ≥306 dB/m via FibroScan®; Liver fat content ≥10%, as assessed by MRI-PDFF) were randomized 3:1 to treatment with GL0034 (uptitration from 0.4 mg-1.6mg for 10 weeks and fixed dose of 2.4 mg for 3 weeks; total dose 17.6mg) or placebo for 13 weeks. The data from strata of post-menopausal females (52-69 years of age) is presented (17 in GL0034 treatment and 5 in placebo). At Week 14, the GL0034-treated females achieved a mean percent change in body weight of -8%, (P<0.001) and sustained beyond initial treatment exposure through Week 17, compared to -2.1% at Week 14 and -1.2% at Week 17 in placebo-treated participants. Further, at week 14 and 17, 76% and 71% GL0034-treated female participants, respectively, achieved weight loss of more than 5%; and one fourth participants achieved a weight loss exceeding 10%. The mean BMI at baseline of GL0034-treated females was 43 kg/m², which improved to 39.7 and 39.8 kg/m² at weeks 14 and 17, respectively. Notably, 47% of female participants in class III and class II obesity group, showed one level lowering of obesity class.
- The liver fat content was significantly decreased from baseline in participants treated with GL0034 with mean percent changes of -28.6% (P<0.01) compared to a change of -2.7% in placebo-treated individuals. The PRO-C3 levels significantly decreased from baseline (-12.6%, P<0.05) as compared to an increase of 11.8% in placebo-treated participants. About 35% of the females achieved >30% of relative liver fat content reduction as compared to none in placebo-treated group.
- The most common AEs occurring in ≥5 participants receiving GL0034 were decreased appetite, early satiety, nausea, dyspepsia, and vomiting.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

About GL0034

GL0034 (utreglutide) is an investigational novel glucagon-like peptide 1 receptor agonist (GLP-1RA) in development as a once-weekly, long-acting, antidiabetic medication in patients with obesity and type 2 diabetes. Further clinical studies are planned to assess clinical safety and effectiveness.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter).

Disclaimer

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contacts

Investors

Dr. Abhishek Sharma
Tel + 91 22 4324 4324, Ext 2929
Tel Direct + 91 22 43242929
Mobile + 91 98196 86016
E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh
Tel + 91 22 4324 4324, Ext 5373
Tel Direct + 91 22 43245373
Mobile + 91 98104 71414
E mail gaurav.chugh@sunpharma.com